Results 71 to 80 of about 8,798 (217)

Neutrophils in cancer: At the crucial crossroads of anti‐tumor and pro‐tumor

open access: yesCancer Communications, Volume 45, Issue 8, Page 888-913, August 2025.
Abstract Neutrophils are important components of the immune system and play a key role in defending against pathogenic infections and responding to inflammatory cues, including cancer. Their dysregulation indicates potential disease risk factors. However, their functional importance in disease progression has often been underestimated due to their ...
Wenpeng Cai   +6 more
wiley   +1 more source

Gamma-delta (γδ) T cells: friend or foe in cancer development?

open access: yesJournal of Translational Medicine, 2018
Background γδ T cells are a distinct subgroup of T cells containing T cell receptors (TCRs) γ and TCR δ chains with diverse structural and functional heterogeneity.
Yijing Zhao, Chao Niu, Jiuwei Cui
doaj   +1 more source

Differential Skewing of Circulating MR1-Restricted and γδ T Cells in Human Psoriasis Vulgaris

open access: yesFrontiers in Immunology, 2020
Psoriasis vulgaris (PV) is a chronic, recurrent inflammatory dermatosis mediated by aberrantly activated immune cells. The role of the innate-like T cells, particularly gammadelta T (γδT) cells and MR1-restricted T lymphocytes, is incompletely explored ...
Vera Plužarić   +11 more
doaj   +1 more source

Harnessing the immunotherapeutic potentials of gamma delta T cells against hematological malignancies

open access: yesHemaSphere, Volume 9, Issue 8, August 2025.
Abstract Gamma delta (γδ) T cells, which constitute about 5%–10% of peripheral blood lymphocytes, play key roles in tumor immunosurveillance and are often enriched within epithelial tissues. They are unique in their Major Histocompatibility Complex‐independent antigen recognition via the γδ T‐cell receptor (TCR) as well as via innate receptors, making ...
Charles Agbuduwe   +2 more
wiley   +1 more source

Gamma/delta T cells as cellular vehicles for anti-tumor immunity

open access: yesFrontiers in Immunology
Adoptive cellular immunotherapy as a new paradigm to treat cancers is exemplified by the FDA approval of six chimeric antigen receptor-T cell therapies targeting hematological malignancies in recent years.
Chelsia Qiuxia Wang   +3 more
doaj   +1 more source

Stimulatory and inhibitory activity of STING ligands on tumor-reactive human gamma/delta T cells

open access: yesOncoImmunology, 2022
Ligands for Stimulator of Interferon Genes (STING) receptor are under investigation as adjuvants in cancer therapy. Multiple effects have been described, including induction of immunogenic cell death and enhancement of CD8 T-cell mediated anti-tumor ...
Ruben Serrano   +5 more
doaj   +1 more source

Role of innate T cells in anti-bacterial immunity [PDF]

open access: yes, 2015
Innate T cells are a heterogeneous group of αβ and γδ T cells that respond rapidly (
Aggarwal   +100 more
core   +1 more source

Potential of gamma/delta T cells for solid tumor immunotherapy

open access: yesFrontiers in Immunology
Gamma/delta T (γδ T)cells possess a unique mechanism for killing tumors, making them highly promising and distinguished among various cell therapies for tumor treatment.
Dantong Zhu   +9 more
doaj   +1 more source

A Simple and Robust Single-Step Method for CAR-Vδ1 γδT Cell Expansion and Transduction for Cancer Immunotherapy

open access: yesFrontiers in Immunology, 2022
The γδT cell subset of peripheral lymphocytes exhibits potent cancer antigen recognition independent of classical peptide MHC complexes, making it an attractive candidate for allogeneic cancer adoptive immunotherapy.
Gabrielle M. Ferry   +7 more
doaj   +1 more source

Efficacy of Axicabtagene Ciloleucel Compared to Historical Treatments for Relapsed/Refractory Diffuse Large B‐Cell Lymphoma of Asian Descent: A Matching Adjusted Indirect Comparison of ZUMA‐1 vs REAL‐TREND

open access: yesHematological Oncology, Volume 43, Issue 3, May 2025.
ABSTRACT To better understand the comparative effectiveness of axicabtagene ciloleucel (axi‐cel) to historical standard of care (SoC) for the treatment of refractory diffused large B‐cell lymphoma (DLBCL) among patients of Asian descent, we conducted a matching‐adjusted indirect treatment comparison (MAIC) of the pivotal ZUMA‐1 trial (NCT02348216) and ...
Frederick L. Locke   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy